Radiation Therapy News and Research

RSS

Radiation therapy (also called radiotherapy, x-ray therapy, or irradiation) is the use of a certain type of energy (called ionizing radiation) to kill cancer cells and shrink tumors. Radiation therapy injures or destroys cells in the area being treated (the “target tissue”) by damaging their genetic material, making it impossible for these cells to continue to grow and divide. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue.

Varian Medical Systems receives IDG's InfoWorld 100 Award for innovative use of IT

Zenprise, Inc., a provider of mobile management software, today announced its customer, Varian Medical Systems Inc., received IDG's InfoWorld 100 Award based on its deployment of the Zenprise MobileManager platform. The InfoWorld 100 Awards recognizes the top 100 most innovative uses of IT initiatives to further business goals.

9 Dec 2009

Two abstracts describing preclinical studies with GMI-1070 selected for oral presentations

GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two abstracts describing preclinical studies with GMI-1070 have been selected for oral presentations at the 51st Annual American Society of Hematology (ASH) meeting being held December 5-8 in New Orleans.

8 Dec 2009

ImmunoGen's SAR3419 holds hope for B-cell non-Hodgkin’s lymphoma

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of encouraging initial clinical findings with SAR3419 at the American Society of Hematology (ASH) 51st Annual Meeting and Exposition. Among the findings reported were responses to SAR3419 – administered as a single agent – among patients with B-cell non-Hodgkin's lymphoma that is refractory to treatment with rituximab (Rituxan®).

8 Dec 2009

Gentium presents evaluation results of Defibrotide for VOD at the ASH conference

Gentium S.p.A. today announced final clinical trial results from the Company’s Phase II/III Pediatric Prevention trial and Phase III Treatment trial for Defibrotide of Hepatic Veno-Occlusive Disease (VOD), which were presented at the American Society of Hematology Conference (ASH) in New Orleans.

8 Dec 2009

New discoveries to treat life-threatening blood disorder presented at ASH annual meeting

A genetic variation that may indicate a patient's risk of developing a potentially life-threatening blood disorder if exposed to certain pharmaceutical therapies or chemicals is one of several medical discoveries scientists at cancer diagnostics leader Quest Diagnostics will present during the 51st American Society of Hematology (ASH) Annual Meeting and Exposition, December 5-8, 2009, in New Orleans, LA.

4 Dec 2009

Protein plays a key role in cancer and DNA repair

A protein that plays a key role in copying DNA also plays a vital role in repairing breaks in it, UC Davis scientists have found. The work is helping researchers understand how cancer cells can resist radiation and chemotherapy, as well as how cells become cancerous in the first place.

4 Dec 2009

Multi-Lumen MammoSite device to treat breast cancer now available at Jupiter Medical Center

Women fighting breast cancer after a lumpectomy have a new weapon in the battle, now available at Jupiter Medical Center's Foshay Cancer Center. Today, the hospital began treating patients with the Multi-Lumen MammoSite(R) device, just approved in September by the FDA.

4 Dec 2009

The Cancer Center at Harrington receives approval to treat its first patients

The Cancer Center at Harrington has received approval to treat its first patients, Harrington Hospital announced today.

4 Dec 2009

Allos Therapeutics to launch the COMPLETE registry for patients with PTCL

Allos Therapeutics, Inc. today announced the launch of an international registry designed to address the urgent need to better understand treatment patterns and outcomes for patients with peripheral T-cell lymphoma (PTCL). The registry, known as COMPLETE (Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment), is a global observational study that will enroll patients with newly-diagnosed PTCL and obtain data regarding longitudinal treatment patterns and outcomes.

3 Dec 2009

Continued rise of PSA value in prostate cancer patients can indicate relapsing disease

Prostate cancer patients who have a prostate-specific antigen (PSA) value of less than or equal to 1.5 at two years after external beam radiation therapy (EBRT) are less likely to have a cancer recurrence and cancer-related death, according to a study in the December 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).

3 Dec 2009

PEG polymer may prevent GI injury during cancer radiotherapy

A non-absorbed, oral co-polymer therapy under development by Midway Pharmaceuticals demonstrated the ability to protect against damage to healthy gastrointestinal tissues and to prevent lethal bacterial infections in animal models of radiation damage.

3 Dec 2009

Researchers discover ability of stem cells in brain cancer glioma to resist radiation therapy

Duke University Medical Center researchers have figured out how stem cells in the malignant brain cancer glioma may be better able to resist radiation therapy. And using a drug to block a particular signaling pathway in these cancer stem cells, they were able to kill many more glioma cells with radiation in a laboratory experiment.

2 Dec 2009

MagForce Nanotechnologies applies for EU regulatory approval of its Nano-Cancer therapy

MagForce Nanotechnologies AG, the Berlin-based medical nanotechnology company majority owned by Nanostart AG, has submitted its application for the European regulatory approval of its Nano-Cancer® therapy.

2 Dec 2009

Development of novel virus can lead to new therapeutic strategy to combat cancer

Ohio State University cancer researchers have developed a tumor-attacking virus that both kills brain-tumor cells and blocks the growth of new tumor blood vessels.

2 Dec 2009

RapidArc radiotherapy technology delivers highly-precise IMRT treatment

Former New Jersey Assemblyman Francis Bodine was surprised and delighted when his radiotherapy treatment sessions for prostate cancer went from about 20 minutes each day to less than five.

2 Dec 2009

CRO to run CEL-SCI's upcoming Phase III clinical trial

CEL-SCI Corporation, a late-stage oncology company and a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases, announced today that it has retained the services of an international Contract Research Organization (CRO) to run CEL-SCI's upcoming Phase III clinical trial in advanced primary head and neck cancer with the Company's lead product candidate, Multikine®.

1 Dec 2009

Gentium announces financial results for the third quarter ended September 30, 2009

Gentium S.p.A. today reported financial results for the quarter ended September 30, 2009.

30 Nov 2009

Varian Medical Systems to exhibit its full range of detectors at RSNA Annual Meeting in Chicago

Varian Medical Systems, Inc., a premier supplier of X-ray tubes and flat panel digital image detectors, will exhibit its full range of detectors at the RSNA Annual Meeting in Chicago, Ill. from November 29 - December 3, 2009. Varian will also be exhibiting X-ray tube technology for multiple modalities as well as specialized cancer treatment technologies.

27 Nov 2009

CyberKnife Robotic Radiosurgery treatment offers new option for cancer patients in Ontario

Ontario marks a milestone with the announcement of the province's first CyberKnife Robotic Radiosurgery treatment option for cancer patients at Juravinski Cancer Centre. The technology will offer many cancer patients an effective alternative to surgery for some cancers.

26 Nov 2009

Advanced radiation delivery techniques can reduce TomoTherapy treatment time

TomoTherapy Incorporated announced today that a research study published in the November 11, 2009 International Journal of Radiation Oncology * Biology * Physics -- commonly known as the Red Journal -- indicated that TomoTherapy(SM) treatment times could be reduced by up to 66 percent using advanced radiation delivery techniques.

25 Nov 2009

Radiation Therapy News and Research

Further Reading

Varian Medical Systems receives IDG's InfoWorld 100 Award for innovative use of IT

Two abstracts describing preclinical studies with GMI-1070 selected for oral presentations

ImmunoGen's SAR3419 holds hope for B-cell non-Hodgkin’s lymphoma

Gentium presents evaluation results of Defibrotide for VOD at the ASH conference

New discoveries to treat life-threatening blood disorder presented at ASH annual meeting

Protein plays a key role in cancer and DNA repair

Multi-Lumen MammoSite device to treat breast cancer now available at Jupiter Medical Center

The Cancer Center at Harrington receives approval to treat its first patients

Allos Therapeutics to launch the COMPLETE registry for patients with PTCL

Continued rise of PSA value in prostate cancer patients can indicate relapsing disease

PEG polymer may prevent GI injury during cancer radiotherapy

Researchers discover ability of stem cells in brain cancer glioma to resist radiation therapy

MagForce Nanotechnologies applies for EU regulatory approval of its Nano-Cancer therapy

Development of novel virus can lead to new therapeutic strategy to combat cancer

RapidArc radiotherapy technology delivers highly-precise IMRT treatment

CRO to run CEL-SCI's upcoming Phase III clinical trial

Gentium announces financial results for the third quarter ended September 30, 2009

Varian Medical Systems to exhibit its full range of detectors at RSNA Annual Meeting in Chicago

CyberKnife Robotic Radiosurgery treatment offers new option for cancer patients in Ontario

Advanced radiation delivery techniques can reduce TomoTherapy treatment time

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News